EGF and breast cancer: Our study suggests that CD99-derived agonist ligands inhibit EGF-induced EGFR dimerization through impairing RhoA-Rac1 signaling-mediated reorganization of the actin cytoskeleton, thereby contributing to the suppression of breast cancer growth.